1354200-00-2Relevant articles and documents
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine
Koltun, Dmitry O.,Parkhill, Eric Q.,Elzein, Elfatih,Kobayashi, Tetsuya,Jiang, Robert H.,Li, Xiaofen,Perry, Thao D.,Avila, Belem,Wang, Wei-Qun,Hirakawa, Ryoko,Smith-Maxwell, Catherine,Wu, Lin,Dhalla, Arvinder K.,Rajamani, Sridharan,Mollova, Nevena,Stafford, Brian,Tang, Jennifer,Belardinelli, Luiz,Zablocki, Jeff A.
, p. 3207 - 3211 (2016)
Previously we disclosed the discovery of potent Late INa current inhibitor 2 (GS-458967, IC50 of 333 nM) that has a good separation of late versus peak Nav1.5 current, but did not have a favorable CNS safety window due to high brain penetration (3-fold higher partitioning into brain vs plasma) coupled with potent inhibition of brain sodium channel isoforms (Nav1.1, 1.2, 1.3). We increased the polar surface area from 50 to 84 ?2 by adding a carbonyl to the core and an oxadiazole ring resulting in 3 GS-462808 that had lower brain penetration and serendipitously lower activity at the brain isoforms. Compound 3 has an improved CNS window (>20 rat and dog) relative to 2, and improved anti-ischemic potency relative to ranolazine. The development of 3 was not pursued due to liver lesions in 7 day rat toxicology studies.
